Health Care Knowledge

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b

  Developed as a chemotherapy medicine, Atriance (nelarabine 250 mg/50 mL) is a specialized therapeutic option by Hematologists in India for the treatment of patients with T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (LBL). Atriance is a brand-name medicine and is frequently referred to by another name Arranon. The company Novartis is liable for manufacturing this drug. Atriance 250 mg/50 mL (5mg/mL) solution is commercially supplied as vials, each vial typically contains 250 mg of Nelarabine. The FDA and EMA approvals of Nelarabine took place in 2005 and 2007 respectively. The medicine is yet to be registered in India by the respective authorities. It is an imported drug, promoted by Novartis. In India, this imported medicine can be accessed through legal and reliable channels. There are several service providers that can legally help in accessing this chemotherapy medication. Atriance - Nelarabine injection price difference is subject to its easy acc

Worldwide, the prevalence of breast cancer is escalating quickly due to numerous risk factors including and increase in the geriatric population, late pregnancy, and certain other dramatic changes in lifestyle, sociocultural, and built environments. TNBC or Triple-Negative Breast Cancer accounts for about 15-20 % of all breast cancer cases. TNBC is characterized by the unavailability of ER, PR, and HER2 receptors. Owing to the lack of targetable receptors, there are limited treatment options for TNBC patients. Until now, chemo remains the mainstay treatment option in order to manage TNBC. Commercially available in 200 mg and 180 mg dosage strength, Trodelvy, a novel targeted therapy developed by Gilead Sciences has been approved to treat certain cancers including TNBC. Trodelvy is also approved for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, and Advanced Bladder Cancer. Trodelvy 180 mg or 200 mg is an ADC directed to Trop-2 receptors, a kind of highly expressed p